Cargando…

Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8(+) T Cells in Non-Melanoma Cancers Compared to Melanoma

SIMPLE SUMMARY: Human tumors are often infiltrated by T cells; however, it remains unclear what proportion of T cells infiltrating tumors are bystander and non-tumor specific. We have investigated qualitative characteristics of these tumor-infiltrating lymphocytes (TILs) based on their gene-expressi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gokuldass, Aishwarya, Draghi, Arianna, Papp, Krisztian, Borch, Troels Holz, Nielsen, Morten, Westergaard, Marie Christine Wulff, Andersen, Rikke, Schina, Aimilia, Bol, Kalijn Fredrike, Chamberlain, Christopher Aled, Presti, Mario, Met, Özcan, Harbst, Katja, Lauss, Martin, Soraggi, Samuele, Csabai, Istvan, Szállási, Zoltán, Jönsson, Göran, Svane, Inge Marie, Donia, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696049/ https://www.ncbi.nlm.nih.gov/pubmed/33198174 http://dx.doi.org/10.3390/cancers12113344

Ejemplares similares

Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens
por: Draghi, Arianna, et al.
Publicado: (2021)

Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know
por: Bol, Kalijn Fredrike, et al.
Publicado: (2020)

CTLA-4 blockade boosts the expansion of tumor-reactive CD8(+) tumor-infiltrating lymphocytes in ovarian cancer
por: Friese, Christina, et al.
Publicado: (2020)

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2020)

Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy
por: Schina, Aimilia, et al.
Publicado: (2023)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
por: Bol, Kalijn Fredrike, et al.
Publicado: (2019)

Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2021)

Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma
por: Mørk, Sofie Kirial, et al.
Publicado: (2022)

Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma
por: Andersen, Rikke, et al.
Publicado: (2014)

Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
por: Lauss, Martin, et al.
Publicado: (2017)

Polyfunctional incompletely differentiated CD8+ T cells accumulates after adoptive transfer of tumor-infiltrating lymphocytes and establish immunological memory in patients with metastatic melanoma
por: Donia, Marco, et al.
Publicado: (2015)

Author Correction: Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
por: Lauss, Martin, et al.
Publicado: (2020)

Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy
por: Chamberlain, Christopher Aled, et al.
Publicado: (2022)

Neoantigen-reactive CD8(+) T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma
por: Kristensen, Nikolaj Pagh, et al.
Publicado: (2022)

Broadening the repertoire of melanoma-associated T-cell epitopes
por: Frøsig, Thomas Mørch, et al.
Publicado: (2015)

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
por: Kverneland, Anders Handrup, et al.
Publicado: (2021)

Effects of Ipilimumab on expanded tumor infiltrating lymphocytes in patients with stage IV malignant melanoma
por: Bjørn, Jon, et al.
Publicado: (2013)

Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes
por: Hulen, Thomas Morgan, et al.
Publicado: (2023)

Tumor genetic heterogeneity analysis of chronic sun‐damaged melanoma
por: Sanna, Adriana, et al.
Publicado: (2019)

NF1‐mutated melanoma tumors harbor distinct clinical and biological characteristics
por: Cirenajwis, Helena, et al.
Publicado: (2017)

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
por: Ellebaek, Eva, et al.
Publicado: (2012)

Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
por: Hansen, Ulla Kring, et al.
Publicado: (2020)

DNA methylation subgroups in melanoma are associated with proliferative and immunological processes
por: Lauss, Martin, et al.
Publicado: (2015)

Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer
por: Kverneland, Anders Handrup, et al.
Publicado: (2020)

Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer
por: Westergaard, Marie Christine Wulff, et al.
Publicado: (2020)

B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?
por: Lauss, Martin, et al.
Publicado: (2022)

BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer
por: Donia, Marco, et al.
Publicado: (2012)

Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes
por: Donia, Marco, et al.
Publicado: (2012)

Adjuvant dendritic cell vaccination in high-risk uveal melanoma patients
por: Bol, Kalijn, et al.
Publicado: (2015)

S76. Adoptive cell therapy of melanoma with autologous tumour infiltrating lymphocytes
por: Svane, I, et al.
Publicado: (2014)

ASO Author Reflections: Frequent Relapses Prior to the Start of Adjuvant Therapy in Stage IIIB/C Melanoma
por: Bloemendal, Martine, et al.
Publicado: (2019)

Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells
por: Weis-Banke, Stine Emilie, et al.
Publicado: (2022)

Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma
por: Bjoern, Jon, et al.
Publicado: (2017)

Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma
por: Soerensen, Anne Vest, et al.
Publicado: (2020)

Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab
por: Kverneland, Anders H., et al.
Publicado: (2018)

Characterization of Ex Vivo Expanded Tumor Infiltrating Lymphocytes from Patients with Malignant Melanoma for Clinical Application
por: Junker, Niels, et al.
Publicado: (2011)

Molecular and genetic diversity in the metastatic process of melanoma
por: Harbst, Katja, et al.
Publicado: (2014)

Correction: Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma
por: Bjoern, Jon, et al.
Publicado: (2018)

BRN2 is a non-canonical melanoma tumor-suppressor
por: Hamm, Michael, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0upnio7rlj6o6r1o1kh2hpf45k